Clinical Trial Update: A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052) [Phase 3]

View source ↗

Summary

Phase 3 trial MK-8591A-052 evaluates switching virologically suppressed HIV-1 patients from bictegravir/emtricitabine/tenofovir alafenamide to a doravirine/isla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Islatravir (Islatravir)
• PIFELTRO (doravirine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1 Infection | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-11-18